venous thrombosis

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathRecurrent thromboembolic event

antithrombotics

not classified
EINSTEIN CHOICE (10mg), 2017    NCTrivaroxaban 10mgaspirin -
DURAC II, 1997     VKAcontrol -
WODIT DVT, 2001     VKAcontrol -
WODIT PE, 2003     VKAcontrol -
AUREC FVII, 2009     VKAcontrol -
DACUS (Siragusa), 2008      NCTVKAcontrol -
PROLONG (Palarati), 2006      NCTVKAcontrol -
Vitotec, 2009     warfarincontrol -
ELATE, 2003     warfarinlow intensity warfarinRisk of bias -
AMPLIFY EXT 2.5mg, 2013     apixaban 2.5mgplacebo -
AMPLIFY EXT 5mg, 2013     apixaban 5mgplacebo -
WARFASA, 2012     aspirinplacebo -
ASPIRE, 2012     aspirinplacebo -
RESONATE, 2013     dabigatranplacebo -
Van Gogh, 2007      NCTidraparinuxplaceboLow risk of bias -
PREVENT, 2003     low-intensity warfarinplaceboLow risk of bias -
EISNTEIN EXT, 2010     rivaroxaban 20mgplacebo -
PADIS-PE (Couturaud), 2015      NCTVKAplaceboLow risk of bias -
LAFIT, 1999     warfarinplaceboLow risk of bias -
Levine, 1995   warfarinplacebo -
THRIVE 3, 2003     ximelagatranplacebo -
REMEDY, 2013   dabigatranwarfarin -
EINSTEIN CHOICE (20mg), 2017    NCTrivaroxaban 20mgaspirin -
Boccalon, 2000     LMWH at homeUFH in hospitalnegative-100%-48%
Chong, 2005     LMWH at homeUFH in hospitalsuggesting-1%-72%
Daskalopoulos, 2005     LMWH at homeUFH in hospitalnegative-52%-20%
Koopman, 1996       LMWH at homeUFH in hospitalnegative-14%-19%
Levine, 1996       LMWH at homeUFH in hospitalnegative-34%-22%
Ramacciotti, 2004     LMWH at homeUFH in hospitalnegative-73%
Faivre et al , 1988   Minoctoparineunfractionated heparinnegative-100%12%
apixaban
AMPLIFY-EXT 2.5mg, 2012      NCTapixaban 2.5mgdiscontinuationLow risk of bias suggesting
AMPLIFY-EXT 5mg, 2012      NCTapixaban 5mgdiscontinuationLow risk of bias suggesting
Botticelli DVT, 2008      NCTapixaban (without LMWH)LMWH/VKAExploratory -
AMPLIFY, 2013      NCTapixaban (without LMWH)LMWH/VKA DOAC without heparin Low risk of bias suggesting-21%
aspirin
WARFASA, 2012    NCTaspirindiscontinuationLow risk of bias suggesting15%
ASPIRE, 2012     aspirindiscontinuationsuggesting-11%
Bemiparin
Kakkar, 2003     BemiparinwarfarinRisk of bias negative
dabigatran
RE-MEDY, 2011      NCTdabigatranwarfarinLow risk of bias suggesting-11%
RE-SONATE, 2011    NCTdabigatrandiscontinuationLow risk of bias suggesting-100%
RE-COVER, 2009      NCTheparin/dabigatranheparin/VKA heparin - DOAC Low risk of bias suggesting-1%
dalteparin
CLOT (Lee), 2003     extended dalteparinstandard treatmentsuggesting-4%-49%
Das, 1996     DalteparinwarfarinRisk of bias negative
Lee, 2003       DalteparinwarfarinRisk of bias suggesting
Holmström, 1992   once daily dalteparintwice daily dalteparinnegative
Partsch, 1996     once daily dalteparintwice daily dalteparinnegative153%
Bratt et al , 1985   Dalteparinunfractionated heparinnegative
Holm et al , 1986   Dalteparinunfractionated heparinnegative+Infini%
Bratt et al, 1990   Dalteparinunfractionated heparinnegative83%-33%
Lindmarker et al , 1993   Dalteparinunfractionated heparinnegative-32%104%
edoxaban
Hokusai-VTE Cancer, 2017      NCTedoxabandalteparinpatients with cancerRisk of bias negative 12%
enoxaparin
Veiga, 2000     EnoxaparinacenocoumarolRisk of bias negative
González-Fajardo, 2008     EnoxaparincoumarinRisk of bias -
Cesarone, 2003   extended enoxaparinstandard treatmentnegative-33%-34%
Deitcher, 2006     extended enoxaparinstandard treatmentnegative1%
Meyer, 2002     extended enoxaparinstandard treatmentnegative-20%-30%
Pini, 1994   EnoxaparinwarfarinRisk of bias negative
Gonzalez-Fajardo, 1999     EnoxaparinwarfarinRisk of bias suggesting
Meyer, 2002     EnoxaparinwarfarinRisk of bias negative
Deitcher, 2003   EnoxaparinwarfarinRisk of bias negative
Merli, 2001     once daily enoxaparintwice daily enoxaparinLow risk of bias negative65%51%
Merli (once daily vs UFH), 2001   once daily enoxaparinUFHLow risk of bias negative19%5%
Simonneau et al , 1993   Enoxaparinunfractionated heparinnegative50%-100%
fondaparinux
MATISSE, 2004   fondaparinuxenoxaparinLow risk of bias negative25%
MATISSE PE, 2003   fondaparinuxheparinRisk of bias negative19%
heparin
Ott importé, 1998   heparin+warfarinplaceboLow risk of bias negative
Krahenbuhl, 1979   subcutaneous heparinintravenous heparin -
Bentley, 1980     subcutaneous heparinintravenous heparinsuggesting-90%
Andersson, 1982     subcutaneous heparinintravenous heparin -
Hull, 1986   subcutaneous heparinintravenous heparinnegative 273%
Doyle, 1987   subcutaneous heparinintravenous heparinnegative2%
Walker, 1987   subcutaneous heparinintravenous heparinsuggesting-85%
Lopaciuk   subcutaneous heparinintravenous heparinnegative-73%
Pini, 1990   subcutaneous heparinintravenous heparinnegative93%
Nielsen importé, 1994     heparin+phenprocoumonphenylbutazone -
idraparinux
Van Gogh (subgroup), 2011     idraparinuxstandard treatmentpatients with cancerExploratory negative-62%
VanGogh DVT, 2007    NCTidraparinux (without heparin)heparin/VKAExploratory suggesting3%
VanGogh PE, 2007    NCTidraparinux (without heparin)heparin/VKARisk of bias negative 79%
logiparin
Siegbahn, 1989   once daily logiparintwice daily logiparinnegative
nadroparin
Lopaciuk, 1999     NadroparinacenocoumarolRisk of bias negative
Lopez-Beret, 2001     NadroparinacenocoumarolRisk of bias negative
Lopez Beret, 2001     extended nadroparinstandard treatmentnegative24%
Charbonnier, 1998     once daily nadroparintwice daily nadroparinLow risk of bias negative-27%-43%
Collaborative European Multicentre, 1991   Nadroparinunfractionated heparinnegative89%183%
Prandoni et al , 1992   Nadroparinunfractionated heparinsuggesting-50%-50%
Lopaciuk et al , 1992   Nadroparinunfractionated heparinnegative-100%-100%
rivaroxaban
SELECT D, 2018     rivaroxabandalteparinpatients with cancerRisk of bias suggesting
EINSTEIN-extension, 2009    NCTrivaroxabandiscontinuationLow risk of bias suggesting -51%
EINSTEIN (subgroup), 2014     rivaroxabanenoxaparinpatients with cancersuggesting-7%
Einstein-DVT Dose-Ranging Study, 2008     rivaroxaban (without LMWH)LMWH/VKA -
Einstein-DVT Evaluation, 2010    NCTrivaroxaban (without LMWH)LMWH/VKA DOAC without heparin Low risk of bias suggesting-23%
Einstein-PE Evaluation, 2012      NCTrivaroxaban (without LMWH)LMWH/VKARisk of bias -
rosuvastatin
VanGogh extension, 2007      NCTidraparinuxdiscontinuationsuggesting
tinzaparin
Romera, 2009     TinzaparinacenocoumarolRisk of bias suggesting-53%
Hull, 2006     extended tinzaparinstandard treatmentnegative5%-56%
Hull, 2002   TinzaparinwarfarinRisk of bias negative
Hull et al , 1992   Tinzaparinunfractionated heparinsuggesting-51%-59%
warfarin
Schulman, 1995     6 months1.5 monthssuggesting-25%
Pinede, 2001     3-6 months1.5-3 monthsnegative32%
Wells (subgroup), 2005     tinzaparindalteparinnegative16%129%
Levine, 1995   warfarindiscontinuationLow risk of bias suggesting-4%
LAFIT (Kearon), 1999       warfarindiscontinuationsuggesting-65%
Agnelli, 2001     warfarindiscontinuationnegative-1%
Agnelli, 2003     warfarindiscontinuationnegative67%
PREVENT (Ridker), 2003     warfarindiscontinuationsuggesting-50%
ELAET (Kearon), 2004     warfarindiscontinuationLow risk of bias negative+Infini%
DURAC (Schulman), 1997     warfarindiscontinuationsuggesting-40%
PROLONG (Palareti), 2006      NCTwarfarindiscontinuationsuggesting17%
ximelagatran
THRIVE III, 2003       ximelagatrandiscontinuationLow risk of bias suggesting-14%
Schulman (subgroup), 2003     ximelagatranplacebopatients with cancer -
Fiessinger , 2005   ximelagatranLMWH/VKALow risk of bias -
THRIVE I, 2003   ximelagatran (without LMWH)LMWH/VKA -

caval filter

caval filter
PREPIC, 1998       caval filterno filterLow risk of bias suggesting

direct factor Xa inhibitors

ximelagatran
THRIVE III, 2003       ximelagatrandiscontinuationLow risk of bias suggesting-14%

direct oral anticoagulant (DAO)

not classified
EINSTEIN CHOICE (20mg), 2017    NCTrivaroxaban 20mgaspirin -
apixaban
AMPLIFY-EXT 2.5mg, 2012      NCTapixaban 2.5mgdiscontinuationLow risk of bias suggesting
AMPLIFY-EXT 5mg, 2012      NCTapixaban 5mgdiscontinuationLow risk of bias suggesting
Botticelli DVT, 2008      NCTapixaban (without LMWH)LMWH/VKAExploratory -
AMPLIFY, 2013      NCTapixaban (without LMWH)LMWH/VKA DOAC without heparin Low risk of bias suggesting-21%
dabigatran
RE-MEDY, 2011      NCTdabigatranwarfarinLow risk of bias suggesting-11%
RE-SONATE, 2011    NCTdabigatrandiscontinuationLow risk of bias suggesting-100%
RE-COVER, 2009      NCTheparin/dabigatranheparin/VKA heparin - DOAC Low risk of bias suggesting-1%
RE-COVER II, 2011    NCTheparin/dabigatranheparin/VKA heparin - DOAC Low risk of bias suggesting
edoxaban
Hokusai-VTE Cancer, 2017      NCTedoxabandalteparinpatients with cancerRisk of bias negative 12%
Edoxaban Hokusai VTE, 2013      NCTheparin/edoxabanheparin/VKA heparin - DOAC Low risk of bias suggesting
idraparinux
Van Gogh (subgroup), 2011     idraparinuxstandard treatmentpatients with cancerExploratory negative-62%
rivaroxaban
SELECT D, 2018     rivaroxabandalteparinpatients with cancerRisk of bias suggesting
EINSTEIN-extension, 2009    NCTrivaroxabandiscontinuationLow risk of bias suggesting -51%
EINSTEIN (subgroup), 2014     rivaroxabanenoxaparinpatients with cancersuggesting-7%
Einstein-DVT Dose-Ranging Study, 2008     rivaroxaban (without LMWH)LMWH/VKA -
Einstein-DVT Evaluation, 2010    NCTrivaroxaban (without LMWH)LMWH/VKA DOAC without heparin Low risk of bias suggesting-23%
Einstein-PE Evaluation, 2012      NCTrivaroxaban (without LMWH)LMWH/VKARisk of bias -
rosuvastatin
VanGogh extension, 2007      NCTidraparinuxdiscontinuationsuggesting
ximelagatran
THRIVE III, 2003       ximelagatrandiscontinuationLow risk of bias suggesting-14%
Schulman (subgroup), 2003     ximelagatranplacebopatients with cancer -
THRIVE I, 2003   ximelagatran (without LMWH)LMWH/VKA -

fibrinolysis

not classified
Kakkar (arvin), 1969   arvinno fibrinolysis -
heparin
Schweizer tPA, 1998   tPA+heparinno fibrinolysisnegative
streptokinase
Arneson, 1978   streptokinaseno fibrinolysisnegative
Common, 1976     streptokinaseno fibrinolysisnegative
Elsharawy, 2002     streptokinaseno fibrinolysisnegative
Schulman, 1986   streptokinaseno fibrinolysisnegative
Tsapogas, 1973   streptokinaseno fibrinolysisnegative
Kakkar (streptokinase), 1969   streptokinaseno fibrinolysisnegative
Schweizer (systemic SK), 2000     streptokinaseno fibrinolysis -
t-pa